The reduction in price target from $4 to $1.35 by Benchmark analyst Bruce Jackson, despite maintaining a Speculative Buy rating, could indicate concerns about the company's future performance or market conditions affecting Cardio Diagnostics Hldgs. This significant decrease in price target is likely to negatively impact investor sentiment and the stock price in the short term.